Results 221 to 230 of about 235,115 (280)

Best Practices for Medical Information Global Response Documents from phactMI and MILE. [PDF]

Pharmaceut Med
Wnorowski S, Niemoller F, Glaetzer A, Tamburri R, Vine E, Flick F, Patel M, Hermes-DeSantis ER.   +7 more
europepmc   +1 more source

Altered Nasal Microbiota in Sinonasal Tumors: A Comparative Analysis of Malignant and Benign Sinonasal Tumors

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Although shifts in nasal microbiota have been well‐documented in inflammatory upper airway conditions, microbiota tumor‐associated alterations remain uncharacterized. This study is the first to compare sinonasal microbiota profiles of patients with malignant tumors (MT), benign tumors (BT), and controls, offering insights into tumor‐
Evan A. Patel, Phillip A. Engen, Glen D. Souza, Sarah Khalife, Donyea Moore, Lauren Kret, Pedro Escobedo, Stefan J. Green, Ankur Naqib, Peter Filip, Peter Papagiannopoulos, Bobby A. Tajudeen, Mahboobeh Mahdavinia, Pete S. Batra   +13 more
wiley   +1 more source

Controversial Nomenclature in Peptide Synthesis: A Call for Clarity. [PDF]

J Pept Sci
Sharma A, Kumar A, de la Torre BG, Albericio F.   +3 more
europepmc   +1 more source

Allergic Rhinitis Amplifies Asthma Risk in Patients With Chronic Rhinosinusitis: A Large‐Scale Retrospective Cohort Analysis

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) and allergic rhinitis (AR) are two highly prevalent airway diseases in the United States. While the coexistence of CRS and asthma is well recognized, less is known about the development of new‐onset asthma in CRS, particularly in the context of comorbid AR. This study assessed the impact of CRS and AR on
Austin J. Lee, Mohamad R. Chaaban
wiley   +1 more source

Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. [PDF]

Cancer Discov
Siegel F, Siegel S, Kotýnková K, Karsli Uzunbas G, Korr D, Tomono H, Andersen S, Denney D, Berger M, Schulze VK, Lewis TA, Kaplan B, Golfier S, Mortier J, Hillig RC, Boemer U, Petersen K, Eis K, Williams S, Rüttinger D, Cherniack AD, Loong HH, Goto K, Grassi P, Meyerson M, Greulich H.   +25 more
europepmc   +1 more source

Aneurysm Wall Enhancement and Probability of Instability in Unruptured Intracranial Aneurysms: A Long‐Term Follow‐Up Study

Annals of Neurology, EarlyView.
Objective Aneurysm wall enhancement (AWE) may predict aneurysm growth and rupture in the short‐term, but there is a lack of long‐term follow‐up studies. We aimed to determine whether unruptured intracranial aneurysms (UIAs) with AWE have a higher probability of aneurysm instability during long‐term follow‐up compared with those without AWE. Methods For
Laura T. van der Kamp, Maarten J. Kamphuis, Olivier Naggara, Thomas Le Tat, Gabriel J. E. Rinkel, Gérard A. P. de Kort, Ruben P. A. van Eijk, Jeroen Hendrikse, Irene C. van der Schaaf, Mervyn D. I. Vergouwen   +9 more
wiley   +1 more source

Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP). [PDF]

Future Oncol
Morgans AK, Chehrazi-Raffle A, Niazi T, Shore ND, Ross AE, Røder A, Gomes AJ, Supiot S, Barthélémy P, Hatano K, Ruiz CBC, Yoshida S, Herrera-Imbroda B, Gratton M, Gschwend JE, Hope TA, Joensuu H, Kuss I, Le Berre MA, Dimova-Dobreva M, Fizazi K.   +20 more
europepmc   +1 more source

Advances and Challenges in Micro/Nanocarrier‐Based Dermal Drug Delivery Systems for Acne Treatment

Advanced NanoBiomed Research, EarlyView.
Topical acne treatment faces challenges from skin barriers and complex causes. Micro/nanocarriers improve drug delivery by enhancing bioavailability, targeting, and duration. Combining carriers creates synergistic effects for systematic intervention.
Jintao Yang, Jie Chen, Yunmiao Ma, Qingwei Zhou, Yu Kong, Yingxiang Chen, Junjie Chi, Haihua Hu   +7 more
wiley   +1 more source

Unphysical Structure Collapse in Quantum Mechanics Calculations With Continuum Solvation. [PDF]

Chemphyschem
Göller AH, Tshitenge DT.
europepmc   +1 more source

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. [PDF]

ESMO Open
Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D.   +19 more
europepmc   +1 more source